|
|
|
|
| LEADER |
01864nmm a2200289 u 4500 |
| 001 |
EB000636742 |
| 003 |
EBX01000000000000000489824 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9783034881036
|
| 100 |
1 |
|
|a Ronald, Allan R.
|e [editor]
|
| 245 |
0 |
0 |
|a Fluoroquinolone Antibiotics
|h Elektronische Ressource
|c edited by Allan R. Ronald, Donald Low
|
| 250 |
|
|
|a 1st ed. 2003
|
| 260 |
|
|
|a Basel
|b Birkhäuser
|c 2003, 2003
|
| 300 |
|
|
|a X, 261 p
|b online resource
|
| 505 |
0 |
|
|a The history of quinolones -- Structure-activity relationships of quinolones -- Epidemiology and mechanisms of resistance -- Improved safety profile of newer fluoroquinolones -- Pharmacokinetics and pharmacodynamics (PK/PD) of fluoro-quinolones: tools for combating bacteria and preventing resistance -- Fluoroquinolones in urinary tract infection -- The quinolones and sexually transmitted infections -- Gastrointestinal and intraabdominal infections -- The quinolones in otitis media and upper respiratory infections -- Quinolones in pneumonia -- Fluoroquinolones for the treatment of respiratory tractinfections other than pneumonia -- Quinolones for the treatment of skin, soft tissue, bone andprosthetic joint infections -- The role of fluoroquinolones in the therapy and prophylaxisof neutropenic patients with cancer -- Less usual indications: Mycobacterial, Brucella, Yersinia,Francisella and other infections -- The quinolones: future prospects
|
| 653 |
|
|
|a Diseases
|
| 653 |
|
|
|a Immunology
|
| 653 |
|
|
|a Pharmacology
|
| 700 |
1 |
|
|a Low, Donald
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Milestones in Drug Therapy
|
| 028 |
5 |
0 |
|a 10.1007/978-3-0348-8103-6
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-0348-8103-6?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615
|